Central nervous system (CNS)
tuberculosis (TB) is a devastating and often life-threatening disease caused by Mycobacterium tuberculosis.
Contezolid, a new
oxazolidinone, has demonstrated potent antimycobacterial activity in both in-vivo and in-vitro studies, with lower toxicity than
linezolid. However, pharmacokinetic data are still not available for
contezolid in the CNS of patients with CNS TB. This article reports the steady-state concentrations of
contezolid in serum and cerebrospinal fluid (CSF) of a patient receiving
contezolid as part of multi-
drug treatment for tuberculous
meningoencephalitis. At weeks 7 and 11 (7 h post-dose) after initiation of
contezolid therapy, the serum concentrations of
contezolid were 9.64 mg/L and 9.36 mg/L, respectively. In CSF, the observed concentrations of
contezolid were 0.54 mg/L and 1.15 mg/L, respectively. The CSF:serum concentration ratios were 0.056 and 0.123 at weeks 7 and 11, respectively. The observed concentrations in CSF were above the minimum inhibitory concentration of
contezolid against M.
tuberculosis, and were close to the estimated serum unbound fraction of
contezolid (10%), suggesting that unbound
contezolid has high CSF permeability.